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Sézary syndrome is a primary cutaneous T-cell lympho-
ma characterized by pruritic erythroderma, peripheral 
lymphadenopathy and the presence of malignant T cells 
in the blood. Unequivocal detection of malignant cells 
in patients with Sézary syndrome is of important diag-
nostic, prognostic and therapeutic value. However, no 
single Sézary syndrome specific cell surface marker has 
been identified. In a cohort of patients with Sézary syn-
drome, CD164 expression on total CD4+ lymphocytes was 
significantly upregulated compared with healthy controls. 
CD164 expression was in most cases limited to CD4+CD26– 
malignant T lymphocytes, unequivocally identified using 
flow-cytometry by the expression of a specific Vβ clone 
for each patient. Increased expression of CD164 may be 
a promising diagnostic parameter and a potential target 
for a CD164-linked therapeutic approach in Sézary syn-
drome. Key words: Sézary syndrome; marker; CD164.
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Cutaneous T-cell lymphomas (CTCL) are the second 
most common group of extranodal non-Hodgkin lympho-
mas, representing approximately 75% of all primary cu-
taneous lymphomas (1). Of all CTCL, mycosis fungoides 
and Sézary syndrome (SS) account for roughly 53% (2). 
SS, characterized by pruritic erythroderma, peripheral 
lymphadenopathy, and the presence of malignant T cells 
in the blood, has a poor prognosis, with a mean overall 
survival of approximately 5 years (3–5). 
Easy and precise detection of malignant cells in the 
blood of patients with SS is of important diagnostic, 
prognostic and therapeutic value and is essential for 
disease monitoring under treatment (6–8). Currently, the 
loss of cell surface markers, such as CD26, CD27 and 
CD7, on malignant T lymphocytes remains one of the 
most consistent features of CTCL and is routinely used 
in the diagnostic workup (9), although their specificity, 
and especially sensitivity, must be interpreted with cau-
tion (10). However, a ubiquitously expressed, single 
clear-cut diagnostic marker allowing for the diagnosis 
of CTCL is yet to be discovered (11). An extensive gene 
expression microarray analysis, performed recently by 
Wysocka et al. (12) found that CD164 is upregulated in 
CD4+ T cells of patients with SS. The aim of the present 
study was to confirm CD164 as a potential marker for 
malignant T cells in the blood of patients with SS.
METHODS
Patients from the Department of Dermatology of the University 
Hospital of Zurich, Switzerland, with previously diagnosed SS 
and with unequivocally identifiable Vβ clonal T-cell popula-
tion (n = 8) were included in the study. Healthy individuals and 
patients with inflammatory skin disease (psoriasis) served as 
a control. The diagnosis of SS was established in all patients 
according to the World Health Organization–European Organi-
zation for Research and Treatment of Cancer criteria for SS (1). 
The study was conducted in accordance with the principles of 
the Declaration of Helsinki and was approved by the Institutional 
Review Board of the University of Zurich (KEK-ZH-Nr. 2015-
0209). Peripheral blood from the patients with SS and psoriasis 
was obtained from the University of Zürich Biobank, funded by 
the University of Zurich University Research Priority Program 
(URPP) in translational cancer biology. All patients agreed to the 
use of the blood, including the generation of cell cultures and other 
materials according the Biobank project (EK No. 647). Blood from 
healthy individuals was obtained as discarded tissue from the blood 
bank of the University Hospital Zurich. All patients with CTCL 
were seen at the Cutaneous Lymphoma Clinic at the Department 
of Dermatology of the University Hospital of Zurich. Patients’ 
characteristics and malignant T-cell burden are shown in Table I.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll centrifugation. Analysis of T cells was performed using 
monoclonal antibodies against human CD3 (clone BW264/56, 
label PerCP; Miltenyi Biotec #130-096-910), CD4 (Clone 
VIT4; label APC-Vio770; Miltenyi Biotec #130-098-153), 
CD26 (Clone BA5b, label PE-Cy7, #302714, BioLegend) and 
CD164 (clone N6B6; label FITC; BD Biosciences #551297). 
Isotype-matched negative control antibodies were used to set 
the gates for positive staining. Vβ clonal T-cell population was 
assessed by flow cytometry using the IOtest Beta Mark TCR 
Vβ Repertoire kit (Beckman Coulter) as previously described 
(8). Annexin V staining (label APC; BD Pharmingen #550474), 
paired with 7-AAD (label PerCP-Cy5; single reagent from the 
FITC BrdU Flow Kit; BD Pharmingen #559619) was used to 
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identify dimethyl-sulphoxide (DMSO)-induced apoptosis (13). 
Analysis was performed on Becton Dickinson FACSCanto 
instruments and data were analysed using FCS Express 5 Flow 
Cytometry RUO and Origin Pro 9.1G Software. Detailed flow 
cytometry methods have been published elsewhere (14, 15).
Proliferation assay
PBMC from patients with SS were labelled with CellTraceTM Far 
Red (Life Technologies; #C34564) and subsequently activated 
with T Cell Activation/Expansion Kit (Miltenyi Biotec #130–091-
441) according to the manufacturer’s instructions. The assay was 
performed in 96-well flat-bottom plates and a total volume of 
200 μl. Proliferation was determined 24, 48 and 72 h after activa-
tion. Detailed proliferation methods are available elsewhere (16).
RESULTS
CD164 cell surface expression on total CD4+ T helper 
lymphocytes from patients with SS was significantly 
upregulated compared with healthy controls and patients 
with benign inflammatory skin disease, namely psoriasis 
(Fig. 1A). The medium fluorescence intensity (MFI) of 
CD164 on total lym phocytes from patients with SS was 
approximately 1200, while the MFI of CD164 on total 
lymphocytes from healthy donors was approximately 
800. As expected, the expression of CD164 was not 
homogenous on the lymphocyte population of patients 
with SS. In most cases, CD4+CD26+ benign T helper 
lymphocytes remained CD164–, while CD4+ lymphocy-
tes with CD26 loss showed increased CD164 expression 
(Fig. 1B). In contrast, CD164 expression was, in most 
cases, independent of CD26 loss in control samples (Fig. 
1C). In patients with SS, mean CD164 expression was 
30.8% on average and varied between patients, ranging 
from 4.3% to 96.0% of CD4+ T cells. Mean CD164 ex-
pression in CD4+ T cells from healthy controls was 8.0% 
on average, ranging from 2.3% to 18.2%. Furthermore, 
CD164 expression on CD4+ T lymphocytes in blood 
from patients with SS was almost exclusively limited to 
CD4+CD26– lymphocytes. The percentage of CD164+ T 
cells was not associated with disease duration, being the 
time of first diagnosis to either death (Pat. Nos 2–4, 7) 
or to discontinued observation at the time of manuscript 
preparation (Pat. Nos  1, 5–6, 8) (Fig. 1D).
As a next step, we analysed whether there was a differ-
ence in the level of expression of CD164 on malignant, 
clonal T cells compared with benign bystander T cells 
in the blood of individual patients with SS. The CD164 
MFI on benign T cells in SS did not differ significantly 
from that on lymphocytes from healthy donors (MFI of 
600 or 800, respectively). In contrast, CD164 expression 
was strongly upregulated (MFI of 1360) on the malignant 
T cells unequivocally identified by the expression of a 
specific Vβ clone (Fig. 2A). Moreover, in most cases (6 
out of 8 patients), a high level of expression of CD164 
Table I. Patients’ clinical characteristics at time of analysis
Pat. No. TCR clone
Clonal cells 
%
Age, years/
Sex
CD4/CD8 
ratio
CD4+ 
CD7– %
CD4+ 
CD26–
Total lymphocyte 
count Treatment
Disease duration, 
years
1 Vβ22 50 62/M 11.5 7 91 1,224 ECP, TS, UVB, B 1
2 Vβ13.2 24.81 61/M 46.9 14 94 18,776 ECP, IFN-α2a, PUVA 5
3 Vβ1 75.99 90/F 19.7 72 63 8,576 ECP, B, TS 11
4 Vβ14 91.5 70/F 72.7 86 97 5,522 ECP, MTX 6
5 Vβ7.1 69.8 67/M 21.2 37 49 1,417 PUVA 4
6 Vβ8 33.77 64/M 18.1 89 100 625 P, SST 6
7 Vβ1 85.44 72/F 13.6 10 99 5,996 ECP 2
8 Vβ22 90.25 74/M 28.7 91 99 1,551 ECP, IFN-γ 3
TCR: T-cell receptor; IFN: interferon; UVB: ultraviolet B; ECP: extracorporeal photochemotherapy; B: bexarotene; TS: topical steroids; MTX: methotrexate; 
P: pralatraxate; PUVA: psoralen + UVA treatment; SST: stem cell transplantation. Reference range: 850–2,500 lymphocytes/µl blood.
Fig. 1. CD164 expression is increased on CD4+ T cells from 
patients with Sézary syndrome (SS). (A) Flow cytometric 
analysis of CD164 expression in blood CD4+ T cells from 
healthy donors (nml), control population of patients with 
inflammatory skin disease (ISD; psoriasis) and from patients 
with SS. (B) Representative example of CD164 expression 
limited to CD4+ CD26- T cells in the blood of a patient with 
SS (plot gated on CD4). (C) Representative control sample 
gated on CD4+ cells from a healthy individual (nml) and a 
patient with inflammatory skin disease (ISD; psoriasis). (D) 
The percentage of  CD164+  T cells in the blood of patients with 
SS do not correlate significantly with the duration of disease. 
Acta Derm Venereol 96
3CD164 in Sézary syndrome
was limited to the malignant T cell clones, while the 
level of expression remained low on non-malignant cells 
(Fig. 2B–D). A more detailed pair-wise comparison of 
CD164 MFI in non-clonal vs. clonal CD4+ T cells in 
each individual patient with SS made it evident that in 
patient No. 3 CD164 expression on clonal malignant T 
cells (MFI=741.92) was not increased in comparison with 
healthy controls; however, it was still twice as high when 
intraindividually compared with non-clonal T cells from 
the same patient (MFI = 370.37) (Fig. 2E; dark orange 
colour-indexed pair). In T cells from patient No. 4, a rela-
tively low expression of CD164 and no intraindividual 
difference between non-clonal (MFI = 452.9) and clonal 
(MFI = 473.92) T cells could be detected. 
In 3 representative patients with SS (Pat. Nos 1, 7, 8), 
further analysis revealed an increased apoptotic rate pa-
ralleled by reduced proliferation in CD164-expressing 
cells (Fig. 3).
DISCUSSION
The prognosis for SS is poor and curative treatment 
options, besides allogeneic stem cell transplan-
tation, are limited. Several new 
therapeutic options have attracted 
strong interest, as they may offer 
the possibility of developing new 
and effective targeted therapies. 
Open-label multicentre phase III 
clinical studies on anti-CD30 and 
anti-CCR4 in relapsed or refractory 
CTCL are active and recruiting and 
an open-label multicentre phase I 
study on a humanized anti-CD158k 
monoclonal antibody is in prepara-
tion (17–22). Nevertheless, other 
markers with potential for targeted 
approach in the treatment of CTCL 
are constantly being investigated. 
CD164 is described as an adhesive 
sialomucin on CD34+ cells with the 
capacity to suppress haematopoietic 
cell proliferation (23). Here, we 
were able to show enhanced CD164 
expression on malignant T cells in 
blood of patients with SS. In an 
independent patients’ sample, we found that CD164 
expression on total lymphocytes from patients with SS 
was significantly upregulated compared with healthy 
controls. CD164 expression was in most cases limited 
to CD4+CD26– malignant T lymphocytes, unequivocally 
identified by the expression of a specific Vβ clone for 
each analysed patient.
These data are in line with the recent finding from 
Wysocka et al. (12) and suggest that increased expres-
sion of CD164 may be a promising diagnostic marker 
for SS. Based on our control population data, we 
propose that flow cytometric identification of  > 20% 
CD164 on CD4+ cells in the blood of erythrodermatic 
patients should at least raise suspicion for SS. 
Previous experimental studies have identified CD164 
as a signalling receptor involved in proliferation, cell 
adhesion and migration in haematopoietic stem and 
progenitor cells (24, 25). Furthermore, recent functio-
nal experimental data have linked CD164 expression 
to progression of ovarian cancer (26), and document 
that targeting CD164 in D283-MED medulloblastoma 
cells and in colon cancer cell line HCT116 suppressed 
tumour proliferation, migration and invasion (27, 28). 
Fig. 2. Increased CD164 expression is restricted to malignant T cells from patients with Sézary 
syndrome (SS). (A) Clonal malignant T cells were definitively identified by staining with T-cell 
receptor Vβ antibodies specific for each patient’s malignant clone. The CD164 expression of 
malignant (clonal) and benign (non-clonal) T cells was evaluated by flow cytometry analysis. (B) 
Representative example of flow cytometric identification of the malignant T-cell clone (red). (C) 
Representative example of increased CD164 expression limited to the malignant T-cell population 
(red). (D) Representative histograms demonstrate the increased mean fluorescent intensity of CD164 
expression in clonal (red line) vs. non-clonal (black line) T cells from a patient with SS. (E) Pair-wise 
comparison of CD164 medium fluorescence intensity (MFI) in non-clonal and clonal CD4+ T cells in 
patients with SS. Each colour-indexed pair represents a data set from an individual patient with SS.
Fig. 3. Apoptosis and proliferation rate in CD164 expressing cells 
in patients with Sézary syndrome (SS). (A) Representative contour 
plots of increased annexin V+/7-AAD+ late apoptotic CD164+ (right 
panel) vs. CD164– (left panel) T cells from a patient with SS. (B) 
Representative dot plot of reduced proliferative activity in CD164+ 
(red dots) vs. CD164– (black dots) T cells from a patient with SS. 
Twenty-four hours after induction of proliferation, proliferative 
activity can be detected in 14.93% [(5.2/34.82)*100%] of all CD164+ 
T cells and in 39.97% [(17.13/42.86)*100%] of all CD164– T cells 
from a representative patient with SS.
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This raises the possibility of a targeted CD164-linked 
therapeutic approach in SS.
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